NTLA — Intellia Therapeutics, Inc.

Is NTLA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Intellia Therapeutics, Inc. (NTLA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $11.60. The rating moved from Neutral to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

Intellia Therapeutics, Inc. (NTLA) operates a high‑upside but high‑uncertainty CRISPR gene‑editing platform with several near‑term clinical and partnership catalysts that could drive material value creation if readouts are positive or deals are announced. The company benefits from a differentiated technology base and favorable industry dynamics that are supporting flows into growth biotech, but it faces significant program‑level, manufacturing, funding, and competitive risks. Near‑term price action is likely to track clinical newsflow and broader risk appetite; longer‑term upside depends on successful trials, regulatory progress, and commercial execution.

Key factors

  • Proprietary CRISPR-based platform with multiple in vivo and ex vivo programs that can produce high-value, binary clinical catalysts (data readouts, INDs, partnerships).
  • Potential for meaningful upside from positive clinical readouts or partnership/licensing deals that would validate in‑vivo gene editing commercial potential.
  • Strategic collaborations and industry interest in biologics/CDMO capacity strengthen sector appetite and could produce readthrough demand for gene‑editing manufacturing and services.
  • Current market tone is mildly risk-on with flows into growth/biotech names, which can support near-term upside in the absence of adverse news.
  • Large addressable markets for certain genetic diseases provide long-term revenue opportunity if safety and efficacy are established.

Risks

  • High clinical and regulatory risk: program-level failures or safety signals could materially reduce valuation.
  • Cash burn and funding risk: ongoing R&D and trial costs may require additional equity raises that dilute shareholders if milestones or partnerships are delayed.
  • Competitive pressure from other gene-editing and gene-therapy companies (alternative editing modalities, rival delivery platforms) could limit commercial opportunity.
  • Manufacturing and delivery challenges for in vivo editing (LNPs, AAV, or other vectors) could impede development or scale-up timelines.
  • Reimbursement, pricing, and payer access uncertainty for one-time or high-cost genetic therapies could constrain uptake even after approval.
  • Macroeconomic and policy risks (rates, geopolitical shocks, healthcare policy changes) that reduce risk appetite or slow deal activity.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for NTLA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.